Terry Porter Email and Phone Number

•Led the External Science & Technology (EST) group of 10 professionals (7 PhD’s), in partnership with key R&D stakeholder groups in the US and Europe (Drug Discovery, Preclinical Development, Clin Pharm, Discovery Medicine, Medicine Development, etc.), to deliver global external science and technology goals including identification, evaluation and negotiation of access to key scientific and enabling/platform technology opportunities sourced from commercial as well as academic, government/not-for-profit entities.

Head of Oncology Licensing responsible for worldwide in-licensing of cancer therapeutics and cancer supportive care products. Core member of the Therapeutic Area Strategy Team (TAST) and CEDD matrix teams. Chaired licensing strategy forum identifying licensing opportunities. Led multidisciplinary Due Diligence teams.

Led a research group that provided protein biochemistry support to multidisciplinary Drug Discovery matrix teams. Development Project Team participation and Program Team leadership roles with emphasis on the research and development of monoclonal antibody-based therapeutics. Co-directed a program evaluating humanized monoclonal antibodies for the treatment and prevention of Respiratory Syncytial Virus (RSV) from inception through Phase III trials of lead candidate.

Successfully developed purification process for ONTAK (IL2-diptheria toxin fusion protein) now approved for cutaneous T-cell lymphoma.